NEU released the results of PH2 trial for PMS on 18/12/23 then held the follow up meeting with the FDA on about 23/9/24!
Then on 27/5/24 NEU released the results of the Pitt-Hopkins Syndrome PH2 Trial .
If the PMS timeline is a rough guide we should expect a FDA follow up meeting for Pitt Hopkins at the end of February or early March.
NEU told us months before the first FDA meeting when it was due. My question is why haven’t NEU spoken about a follow up meeting for Pitt-Hopkins. Are NEU working towards a ph3 trial such as PMS. Or have they put the progress of the program to the side for the moment.
Maybe we will hear news shortly. Or just maybe all of those meetings at JPM are forming the basis af discussion in the Boardroom, to decide on the path forward for NEU.
I do remember JP saying a while back that there was a lot of options to consider before deciding on the direction NEU would take from here.
NEU Price at posting:
$14.60 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)